Lv31
394 积分 2023-01-11 加入
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
3天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
4天前
已完结
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
4天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4天前
已完结
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
5天前
已完结
Targeted delivery of albumin nanoparticles for breast cancer: A review
14天前
已完结
Chapter 7 - The perivascular niche
26天前
已完结
Interstitial lung disease: Current concepts of pathogenesis, staging and therapy
27天前
已完结
Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia?
27天前
已完结
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
1个月前
已完结
皖公网安备34019202002308
